Novavax Initiates NVX-CoV2373 (COVID-19 vaccine booster) in P-III (PREVENT-19) Trial for COVID-19 in Adolescents
Shots:
- The company has initiated 1st booster doses in a pediatric expansion of the P-III (PREVENT-19) trial to evaluate NVX-CoV2373 with Matrix-M adjuvant in a ratio (2:1) in 29,960 patients aged 12 through 17yr. with COVID-19 at 73 sites in the US. Patients are eligible to receive a 3rd booster dose of NVX-CoV2373
- The objective of the post-booster dose includes the assessment of humoral immune response 28 days after the booster dose. The results are expected in H2’22
- The results from the P-III (PREVENT-19) trial showed 90.4% efficacy, robust Ab response after 2nd dose, was well-tolerated Novavax' COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a vial containing 10 doses
Ref: PR Newswire | Image: Novavax
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
